A Case Report with Severe Thrombocytopenia Induced by Axitinib

Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma. Axitinib is ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Koksal, Ulkuhan I., Goffin, Janeiro Valle, Lewis, Brian, Sartor, Oliver A., Belyaeva, Elizaveta, Socola, Francisco, Barata, Pedro C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029294/
https://www.ncbi.nlm.nih.gov/pubmed/32089908
http://dx.doi.org/10.1155/2020/7520783
_version_ 1783499138889940992
author Koksal, Ulkuhan I.
Goffin, Janeiro Valle
Lewis, Brian
Sartor, Oliver A.
Belyaeva, Elizaveta
Socola, Francisco
Barata, Pedro C.
author_facet Koksal, Ulkuhan I.
Goffin, Janeiro Valle
Lewis, Brian
Sartor, Oliver A.
Belyaeva, Elizaveta
Socola, Francisco
Barata, Pedro C.
author_sort Koksal, Ulkuhan I.
collection PubMed
description Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma. Axitinib is associated with a safety profile very similar to other anti-VEGFR inhibitors but usually with fewer hematologic adverse events, due to the selectivity for VEGF. In this report, we presented a rare case of grade 4 axitinib-induced thrombocytopenia, not observed with other antiangiogenic therapies. We discuss the differential diagnostic work-up, the necessary multidisciplinary approach, and the successful management of the case.
format Online
Article
Text
id pubmed-7029294
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-70292942020-02-21 A Case Report with Severe Thrombocytopenia Induced by Axitinib Koksal, Ulkuhan I. Goffin, Janeiro Valle Lewis, Brian Sartor, Oliver A. Belyaeva, Elizaveta Socola, Francisco Barata, Pedro C. Case Rep Hematol Case Report Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). This agent is approved as monotherapy or in combination with immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma. Axitinib is associated with a safety profile very similar to other anti-VEGFR inhibitors but usually with fewer hematologic adverse events, due to the selectivity for VEGF. In this report, we presented a rare case of grade 4 axitinib-induced thrombocytopenia, not observed with other antiangiogenic therapies. We discuss the differential diagnostic work-up, the necessary multidisciplinary approach, and the successful management of the case. Hindawi 2020-02-07 /pmc/articles/PMC7029294/ /pubmed/32089908 http://dx.doi.org/10.1155/2020/7520783 Text en Copyright © 2020 Ulkuhan I. Koksal et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Koksal, Ulkuhan I.
Goffin, Janeiro Valle
Lewis, Brian
Sartor, Oliver A.
Belyaeva, Elizaveta
Socola, Francisco
Barata, Pedro C.
A Case Report with Severe Thrombocytopenia Induced by Axitinib
title A Case Report with Severe Thrombocytopenia Induced by Axitinib
title_full A Case Report with Severe Thrombocytopenia Induced by Axitinib
title_fullStr A Case Report with Severe Thrombocytopenia Induced by Axitinib
title_full_unstemmed A Case Report with Severe Thrombocytopenia Induced by Axitinib
title_short A Case Report with Severe Thrombocytopenia Induced by Axitinib
title_sort case report with severe thrombocytopenia induced by axitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029294/
https://www.ncbi.nlm.nih.gov/pubmed/32089908
http://dx.doi.org/10.1155/2020/7520783
work_keys_str_mv AT koksalulkuhani acasereportwithseverethrombocytopeniainducedbyaxitinib
AT goffinjaneirovalle acasereportwithseverethrombocytopeniainducedbyaxitinib
AT lewisbrian acasereportwithseverethrombocytopeniainducedbyaxitinib
AT sartorolivera acasereportwithseverethrombocytopeniainducedbyaxitinib
AT belyaevaelizaveta acasereportwithseverethrombocytopeniainducedbyaxitinib
AT socolafrancisco acasereportwithseverethrombocytopeniainducedbyaxitinib
AT baratapedroc acasereportwithseverethrombocytopeniainducedbyaxitinib
AT koksalulkuhani casereportwithseverethrombocytopeniainducedbyaxitinib
AT goffinjaneirovalle casereportwithseverethrombocytopeniainducedbyaxitinib
AT lewisbrian casereportwithseverethrombocytopeniainducedbyaxitinib
AT sartorolivera casereportwithseverethrombocytopeniainducedbyaxitinib
AT belyaevaelizaveta casereportwithseverethrombocytopeniainducedbyaxitinib
AT socolafrancisco casereportwithseverethrombocytopeniainducedbyaxitinib
AT baratapedroc casereportwithseverethrombocytopeniainducedbyaxitinib

Ejemplares similares